475 related articles for article (PubMed ID: 26155597)
1. Risk of HIV-1 acquisition among women who use diff erent types of injectable progestin contraception in South Africa: a prospective cohort study.
Noguchi LM; Richardson BA; Baeten JM; Hillier SL; Balkus JE; Chirenje ZM; Bunge K; Ramjee G; Nair G; Palanee-Phillips T; Selepe P; van der Straten A; Parikh UM; Gomez K; Piper JM; Watts DH; Marrazzo JM;
Lancet HIV; 2015 Jul; 2(7):e279-87. PubMed ID: 26155597
[TBL] [Abstract][Full Text] [Related]
2. Use of injectable hormonal contraception and women's risk of herpes simplex virus type 2 acquisition: a prospective study of couples in Rakai, Uganda.
Grabowski MK; Gray RH; Makumbi F; Kagaayi J; Redd AD; Kigozi G; Reynolds SJ; Nalugoda F; Lutalo T; Wawer MJ; Serwadda D; Quinn TC; Tobian AAR
Lancet Glob Health; 2015 Aug; 3(8):e478-e486. PubMed ID: 26094162
[TBL] [Abstract][Full Text] [Related]
3. Hormonal contraception and the risk of HIV acquisition: an individual participant data meta-analysis.
Morrison CS; Chen PL; Kwok C; Baeten JM; Brown J; Crook AM; Van Damme L; Delany-Moretlwe S; Francis SC; Friedland BA; Hayes RJ; Heffron R; Kapiga S; Karim QA; Karpoff S; Kaul R; McClelland RS; McCormack S; McGrath N; Myer L; Rees H; van der Straten A; Watson-Jones D; van de Wijgert JH; Stalter R; Low N
PLoS Med; 2015 Jan; 12(1):e1001778. PubMed ID: 25612136
[TBL] [Abstract][Full Text] [Related]
4. Association between injectable progestin-only contraceptives and HIV acquisition and HIV target cell frequency in the female genital tract in South African women: a prospective cohort study.
Byrne EH; Anahtar MN; Cohen KE; Moodley A; Padavattan N; Ismail N; Bowman BA; Olson GS; Mabhula A; Leslie A; Ndung'u T; Walker BD; Ghebremichael MS; Dong KL; Kwon DS
Lancet Infect Dis; 2016 Apr; 16(4):441-8. PubMed ID: 26723758
[TBL] [Abstract][Full Text] [Related]
5. Hormonal contraception and the risk of HIV acquisition among women in South Africa.
Morrison CS; Skoler-Karpoff S; Kwok C; Chen PL; van de Wijgert J; Gehret-Plagianos M; Patel S; Ahmed K; Ramjee G; Friedland B; Lahteenmaki P
AIDS; 2012 Feb; 26(4):497-504. PubMed ID: 22156973
[TBL] [Abstract][Full Text] [Related]
6. HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial.
Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial Consortium
Lancet; 2019 Jul; 394(10195):303-313. PubMed ID: 31204114
[TBL] [Abstract][Full Text] [Related]
7. Prospective study of hormonal contraception and women's risk of HIV infection in South Africa.
Myer L; Denny L; Wright TC; Kuhn L
Int J Epidemiol; 2007 Feb; 36(1):166-74. PubMed ID: 17175547
[TBL] [Abstract][Full Text] [Related]
8. Injectable progestin contraceptive use and risk of HIV infection in a South African family planning cohort.
Kleinschmidt I; Rees H; Delany S; Smith D; Dinat N; Nkala B; McIntyre JA
Contraception; 2007 Jun; 75(6):461-7. PubMed ID: 17519153
[TBL] [Abstract][Full Text] [Related]
9. Use of injectable hormonal contraception and HSV-2 acquisition in a cohort of female sex workers in Vancouver, Canada.
Socías ME; Duff P; Shoveller J; Montaner JSG; Nguyen P; Ogilvie G; Shannon K
Sex Transm Infect; 2017 Jun; 93(4):284-289. PubMed ID: 27821613
[TBL] [Abstract][Full Text] [Related]
10. Injectable and oral contraceptives and risk of HIV acquisition in women: an analysis of data from the MDP301 trial.
Crook AM; Ford D; Gafos M; Hayes R; Kamali A; Kapiga S; Nunn A; Chisembele M; Ramjee G; Rees H; McCormack S
Hum Reprod; 2014 Aug; 29(8):1810-7. PubMed ID: 24838704
[TBL] [Abstract][Full Text] [Related]
11. WHO special programme of research, development and research training in human reproduction. Task force on long-acting agents for the regulation of fertility.
Contraception; 1982 Jan; 25(1):1-11. PubMed ID: 6460593
[TBL] [Abstract][Full Text] [Related]
12. Prevalence and Incidence of Sexually Transmitted Infection in Injectable Progestin Contraception Users in South Africa.
Noguchi LM; Marrazzo JM; Richardson B; Hillier SL; Balkus JE; Palanee-Phillips T; Nair G; Panchia R; Piper J; Gomez K; Ramjee G; Chirenje ZM
Front Reprod Health; 2021 Jul; 3():. PubMed ID: 35669097
[TBL] [Abstract][Full Text] [Related]
13. Oral and injectable contraceptive use and HIV acquisition risk among women in four African countries: a secondary analysis of data from a microbicide trial.
Balkus JE; Brown ER; Hillier SL; Coletti A; Ramjee G; Mgodi N; Makanani B; Reid C; Martinson F; Soto-Torres L; Abdool Karim SS; Chirenje ZM
Contraception; 2016 Jan; 93(1):25-31. PubMed ID: 26519646
[TBL] [Abstract][Full Text] [Related]
14. Effects of the copper intrauterine device versus injectable progestin contraception on pregnancy rates and method discontinuation among women attending termination of pregnancy services in South Africa: a pragmatic randomized controlled trial.
Hofmeyr GJ; Singata-Madliki M; Lawrie TA; Bergel E; Temmerman M
Reprod Health; 2016 Apr; 13():42. PubMed ID: 27091008
[TBL] [Abstract][Full Text] [Related]
15. Responding to the ECHO trial results: modelling the potential impact of changing contraceptive method mix on HIV and reproductive health in South Africa.
Smith JA; Beacroft L; Abdullah F; Buthelezi B; Makua M; Morroni C; Ramjee G; Velasquez C; Hallett TB
J Int AIDS Soc; 2020 Oct; 23(10):e25620. PubMed ID: 33030312
[TBL] [Abstract][Full Text] [Related]
16. Hormonal contraceptive use and women's risk of HIV acquisition: priorities emerging from recent data.
Ralph LJ; Gollub EL; Jones HE
Curr Opin Obstet Gynecol; 2015 Dec; 27(6):487-95. PubMed ID: 26536211
[TBL] [Abstract][Full Text] [Related]
17. Effects of injectable contraception with depot medroxyprogesterone acetate or norethisterone enanthate on estradiol levels and menstrual, psychological and behavioral measures relevant to HIV risk: The WHICH randomized trial.
Singata-Madliki M; Smit J; Beksinska M; Balakrishna Y; Avenant C; Beesham I; Seocharan I; Batting J; Hapgood JP; Hofmeyr GJ
PLoS One; 2024; 19(3):e0295764. PubMed ID: 38530848
[TBL] [Abstract][Full Text] [Related]
18. Norethisterone Enanthate Increases Mouse Susceptibility to Genital Infection with Herpes Simplex Virus Type 2 and HIV Type 1.
Quispe Calla NE; Vicetti Miguel RD; Torres AR; Trout W; Gabriel JM; Hatfield AM; Aceves KM; Kwiek JJ; Kaur B; Cherpes TL
Immunohorizons; 2020 Feb; 4(2):72-81. PubMed ID: 32047094
[TBL] [Abstract][Full Text] [Related]
19. Hormonal contraceptive methods and risk of HIV acquisition in women: a systematic review of epidemiological evidence.
Polis CB; Phillips SJ; Curtis KM; Westreich DJ; Steyn PS; Raymond E; Hannaford P; Turner AN
Contraception; 2014 Oct; 90(4):360-90. PubMed ID: 25183264
[TBL] [Abstract][Full Text] [Related]
20. Counting the costs: comparing depot medroxyprogesterone acetate and norethisterone oenanthate utilisation patterns in South Africa.
Smit J; Gray A; McFadyen L; Zuma K
BMC Health Serv Res; 2001; 1():4. PubMed ID: 11401729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
